Enbridge Inc.

Enbridge Inc. (NYSE: ENB) is an energy infrastructure company with business platforms that include a network of crude oil, liquids and natural gas pipelines, regulated natural gas distribution utilities and renewable power generation.

Key Highlights:

• Increasing uncertainties over oil demand amid resurging cases of Delta variant.
• Heightened transportation costs could create pressure on the margin profile of the company.
• Despite ENB shares are hovering near 52W High, the Average Directional Index (ADI) is indicating lack of strength in the recent uptrend as it is hovering below 20.
• Further, 14-day RSI is falling and hovering in a neutral zone with bearish bias.

Conclusion: Despite ENB is fundamentally strong company, with industry leading margin profile and balance sheet strength. The overall oil industry has become quite volatile on the back of resurgence in Delta variant cases in China and Western economies, which is throwing a lot of uncertainties over near-term oil demand. Further, technical indicators are sideways. Therefore, we recommend a “Watch” rating on the stock at the closing price of USD 39.21 on August 16, 2021 until a clear trend emerge out from this sideways trend.

Source: REFINITIV, Analysis by Kalkine Group

Fisker Inc

Fisker Inc. (NYSE: FSR), formerly Spartan Energy Acquisition Corp., is an automotive company. The Company designs and manufactures electric vehicles.

Key Highlights

• Negative Operating margin, EBITDA margin and Net Margin.
• MACD oscillator registered a crossover, where MACD oscillator moved below the 9-day SMA signal line.
• Negative Spread between 12-day and 26-day EMA
• 14-day RSI falling and indicating a bearish move from the current trading levels.

Conclusion: Shares of FSR are hovering in a bearish territory, and at the last closing, its shares traded below the crucial short-term as well as long-term moving averages of 200-day and 50-day SMAs. Further, on the last trading day, the leading momentum indicator, the Moving Average Convergence Divergence (MACD) moved below the 9-day SMA signal line and spread between 12-day and 26-day EMAs is negative, another bearish trend. Therefore, we recommend an “Avoid” rating at the stock at the closing price of USD 14.13 on August 16, 2021.

Source: REFINITIV, Analysis by Kalkine Group

Dare Bioscience, Inc

Dare Bioscience, Inc. (NASDAQ – DARE) is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health.

Key Highlights:

• Submitted New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June, which received Priority Review with a PDUFA target date of December 7, 2021.
• Commenced the Phase 2b RESPOND study of Sildenafil Cream, 3.6%, a potential first-in-category product in development to treat female sexual arousal disorder, a physiological condition for which there are no FDA approved products.
• The company is yet to receive any approval from FDA. Any negative outcome from the FDA review would affect the business prospects.
• The company is in early stage and yet to generate revenue.
• Losses expanded in the June quarter of 2021 at Operating level and bottom-line losses also soared up.
• Stock Moved below the 200-day, and 50-day SMAs, which is a bearish indicator.
• 14-day RSI falling and hovering in a neutral zone with bearish bias at 46.
• MACD oscillator could move below the 9-day SMA signal line in next few trading session, as MACD is falling.

Conclusion: The company sales has not yet started, despite that its shares are already up approximately 33.3% in a year over period. Further, technical have turned bearish with its shares on the last trading session moved below the crucial short-term as well as long-term supports levels and charted into a long-term bearish zone. Hence, we recommend an “Avoid” rating on the stock at the closing price of USD 1.52 on August 16, 2021.

Source: REFINITIV, Analysis by Kalkine Group

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.